OPN 2853
Alternative Names: OPN-2853; PLX-2853Latest Information Update: 15 Dec 2025
At a glance
- Originator Plexxikon
- Developer Daiichi Sankyo Company; Opna Bio; University of Birmingham
- Class Antineoplastics; Small molecules
- Mechanism of Action BRD4 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Myelofibrosis
- Discontinued Acute myeloid leukaemia; Graft-versus-host disease; Gynaecological cancer; Haematological malignancies; Myelodysplastic syndromes; Ovarian cancer; Prostate cancer; Solid tumours
Most Recent Events
- 08 Dec 2025 Efficacy data from the phase I PROMise trial in Myelofibrosis released by Opna Bio
- 09 Dec 2024 Interim adverse events and efficacy data from the phase-I PROMise trial in Myelofibrosis released by Opna Bio ,
- 02 Feb 2024 OPN 2853 is available for licensing as of 24 Jan 2024 (https://www.opnabio.com/pipeline/)